The global pet supplements market is moving beyond conventional dosage forms. As pet owners increasingly expect the same level of formulation sophistication they see in human nutrition, oral dissolvable films (ODFs) are emerging as one of the most discussed delivery innovations in the sector. This article examines the technology behind fast-dissolve films, the market signals supporting their growth, and the OEM/ODM capabilities that make the format practical for brand owners.

Industry Context: Where Pet Supplement Delivery Stands Today

Pet health supplements have historically been offered as tablets, capsules, powders, or liquids. These formats are familiar to manufacturers and consumers alike, but they come with well-documented limitations. Many pets refuse pills or avoid flavored powders, and the digestive process can reduce the bioavailability of active ingredients. Oral dissolvable films offer an alternative route: a thin, stamp-sized film that disintegrates on the tongue or cheek and delivers nutrients through the oral mucosa. This approach is not new to human pharmaceuticals, but its application in pet supplements is still early-stage and increasingly commercialized.

Wuxi Novohope Biotechnology Co., Ltd. (Novohope) is a manufacturer focused on this specific delivery format. Established in September 2025 and based in Wuxi, China, the company develops pet food and nutrition solutions — primarily oral fast-dissolving films and orodispersible tablets — and positions itself as one of the first global brand enterprises to release pet oral dissolvable film health products. Its product portfolio covers seven formula series: COAT+, EYES+, CALM+, BONE+, HEART+, PROBIO, and Fit+.

Problem and Opportunity: Compliance and Bioavailability

Traditional oral supplements face two structural challenges in pets: physiological absorption barriers and feeding resistance. According to Novohope's technical documentation, the canine and feline digestive system presents a relatively short intestinal tract — under 1.2 meters — combined with high gastric acidity, typically a pH range of 1 to 3. These conditions can degrade active ingredients before they are absorbed, reducing the effective dose reaching the bloodstream. The company claims that traditional products achieve an absorption rate of approximately 35%, though this figure is presented as internal data and should be treated as a first-party claim.

The second constraint is behavioral. Pets frequently reject pills, resist being forced to swallow capsules, or avoid powders mixed into food. This creates inconsistent dosing — a well-known problem in daily care routines. Oral films address both issues. Because the film dissolves quickly in saliva and is absorbed through the oral mucosa, it can bypass the harsh gastric environment. The format also offers high palatability, which reduces the stress associated with forced feeding and helps maintain consistent intake.

Brand Solution: Novohope's Oral Film Product Line

Novohope's product strategy is organized around functional health goals rather than single ingredients. The seven series — COAT+ (coat and skin), EYES+ (eye care and tear stain care), CALM+ (calming and stress relief), BONE+ (joint care and mobility support), HEART+ (cardiovascular care), PROBIO (digestive care), and Fit+ (weight management) — are each available in an oral fast-dissolving format.

The company's formulation philosophy emphasizes palatability and rapid disintegration. Its core claim is that the oral melting film — described as a film the size of a postage stamp — melts within 10 seconds when it contacts saliva, allowing active ingredients to be absorbed directly through the oral mucosa and enter the circulatory system, bypassing the gastric and intestinal digestive process entirely.

Technical Explanation: How Oral Mucosal Absorption Works

The mechanism behind oral dissolvable films differs fundamentally from that of ingestible capsules or chewables. When a film is placed in the mouth, it hydrates quickly and adheres to the mucosal surface. The active ingredients dissolve in saliva and are absorbed through the oral mucosa, which is highly vascularized. This route enables direct entry into the systemic circulation and avoids first-pass hepatic metabolism to a significant degree.

For pet applications, this matters for two reasons. First, it bypasses the short intestinal tract and high gastric acidity that can interfere with nutrient integrity. Second, it enables a faster onset of absorption compared to ingredients that must travel through the gastrointestinal tract. Novohope states that absorption rate can reach up to 95%, which it contrasts with the roughly 35% absorption level seen in traditional products. These figures are company-provided claims and not independently verified, but they define the product's performance positioning in marketing materials.

Novohope's technical team comes from the Wahsheer Biotechnology Laboratory at the Chinese University of Hong Kong, a research environment where Nobel Prize recipients have been located. This background informs the company's approach to oral film matrix design, ingredient stability, and taste masking. The R&D team is composed of 12 engineers, and the company expanded its R&D and marketing center in Shekou, Shenzhen, in June 2026.

Application and Use Cases: From Private Label to Chain Retail

The practical application of Novohope's oral films extends beyond a single brand. The company operates in brand agency, distribution, OEM, and ODM models, and has worked with customers across Germany, the UAE, Canada, Australia, France, and the United States. According to a documented case, Novohope products have been successfully used by EM private label production and ODM customized formula development clients. The case involved a quantity of 200,000 units, distributed through chain supermarkets and retail stores, with a documented engagement spanning three years. Reported results include boosted pet health category sales volume, favorable market feedback, and stable repeat orders.

The emphasis on ease of use is central to these adoption stories. Unlike pills that may require force-feeding, oral films are presented as a low-stress option for pets. The case highlights three product attributes: green safety, easy use, and low resistance from pets. These attributes align with the purchasing logic of retail buyers: a supplement that a pet accepts willingly is more likely to see consistent consumption, which in turn supports category growth.

Market Trend Analysis: Demand Signals and Regional Momentum

External market data supports the relevance of this format shift. According to Grand View Research, the global pet supplements market is valued at approximately USD 2.8 billion in 2025, with projected growth to USD 4.6 billion by 2033. Mordor Intelligence estimates that the pet dietary supplements segment specifically will reach USD 5.11 billion by 2026, growing at a CAGR of 7.42% through 2031. These figures come from two separate research firms and reflect a category that continues to expand.

Geographically, North America accounted for 48.1% of global revenue share in 2025, according to Grand View Research, making it the dominant regional market for pet supplements. Mordor Intelligence identifies Asia-Pacific as the fastest-growing region, driven by rising pet humanization and increased healthcare expenditure in China and India. This regional dynamic is relevant for manufacturers with export-oriented production. Novohope's export ratio is 95%, with primary markets in Europe, America, Britain, the Middle East, Japan, and South Korea.

Within the delivery format segment, oral dissolvable film technology is emerging in the pet sector. Market Reports World notes that current ODF innovations are focusing on disintegration times below 25 seconds and taste-masking palatability improvements of up to 47%. Novohope's stated disintegration time of 10 seconds positions it within this performance envelope, and the company's product line reflects the industry's broader direction toward faster, more palatable delivery systems.

Comparison with Traditional Delivery Formats

When evaluating oral films against conventional formats, several functional differences become clear. Tablets and capsules are familiar to manufacturers and have established regulatory acceptance, but they are more likely to be rejected by pets. Powders offer dosing flexibility but can be messy and may alter food flavor. Liquids allow precise dosing but require more careful packaging and refrigeration in some cases.

Oral films combine the convenience of a single-unit dose with rapid dissolution and direct mucosal absorption. They avoid the need for water, reduce the risk of spitting out, and do not require pets to chew. From a brand owner's perspective, the format also offers a clear point of differentiation in a crowded category.

One honest limitation should be noted: oral dissolvable films are still a relatively small category within pet supplements when compared to tablets and chewables. The format's long-term acceptance depends on consumer education, retailer familiarity, and regulatory clarity for novel delivery forms. There is also a formulation constraint — not all supplement ingredients can be easily incorporated into a thin film at effective dosages. As a manufacturer, Novohope mitigates this through ODM formula development, where custom ingredients are evaluated for compatibility with the film matrix before production.

Quality Control and Manufacturing Reliability

For buyers evaluating an ODM partner, quality assurance is as important as the dosage form. Novohope's manufacturing workflow includes 100% full inspection before delivery and third-party authoritative sampling testing. This dual-layer approach is designed to catch defects at the factory level while providing customers with independent verification.

The company also pursues compliance credentials relevant for export markets. In July 2026, Novohope completed FDA food facility registration and obtained GS1 international product codes. The FDA registration number is 18753066908. Products have passed professional certifications including SDS (Safety Data Sheet) and COA (Certificate of Analysis). These certifications cover different products; for example, the COAT+ and BONE+ series have SDS certification under the OSHA Hazard Communication Standard, while the EYES+ series is documented under US FDA 21 CFR 175.300 test procedures.

Production capacity is another practical consideration. Novohope operates a 20,000 m² facility with an annual output capacity of 200,000,000 boxes. The manufacturing capability supports both OEM and ODM projects, including custom recipes, private packaging design, and other customized requirements. The standard lead time is 35–45 days, with a minimum order quantity of 3,000 units per SKU.

Future Outlook: What This Means for Pet Supplement Brands

As the pet supplements market continues to grow — with global values projected between USD 4.6 billion and USD 5.11 billion by the late 2020s, depending on the research source — the need for differentiated, pet-friendly delivery formats is likely to increase. Oral dissolvable films offer a pathway toward better compliance and higher perceived efficacy, especially for owners whose pets are picky eaters or resistant to traditional dosing.

Novohope's trajectory reflects this momentum. The company made its international debut in May 2026 at the International Pet Exhibition in Nuremberg, Germany, where it showcased six products and reports having received over 700 global customers and reached more than 100 potential clients. It later opened a new R&D and marketing center in Shekou, Shenzhen, in June 2026, signaling continued investment in formulation science. The company was selected for the "Feifeng Talent Program" — the Leading Technological Talent Project in 2025 — and was shortlisted for the 2026 Wuxi Taihu Cup International Innovation Competition.

For brands and distributors evaluating suppliers, the key decision criteria are likely to be: formulation capability, manufacturing certifications, export experience, and the ability to support custom branding. ODF technology, while not yet the dominant format, represents a commercially available and increasingly tested option within this framework.

FAQ

What is Novohope's core product technology?

Novohope is a pet nutrition manufacturer specializing in oral fast-dissolving films and orally disintegrating tablets. Its core technology uses oral mucosal absorption: the film melts in saliva within 10 seconds, and the company states that active ingredients enter the circulatory system directly, with an absorption rate of up to 95%. This mechanism is intended to bypass the digestive degradation that can occur with traditional oral supplements.

What certifications does Novohope hold?

In July 2026, Novohope completed FDA food facility registration (registration number 18753066908) and obtained GS1 international product codes. Products also passed professional certifications such as SDS (Safety Data Sheet) and COA (Certificate of Analysis). Specific tests include OSHA Hazard Communication Standard 29 CFR 1910.1200 for SDS and US FDA 21 CFR 175.300 for select eye-care formulations.

What OEM/ODM capabilities does Novohope offer?

Novohope supports production modes including brand agency, distribution, OEM, and ODM. Customization options cover recipe formulation, brand identity, packaging design, and other requirements. The company reports a monthly capacity of 200,000,000 units, a lead time of 35–45 days, and a minimum order quantity of 3,000 units per SKU.

What quality control does Novohope apply before delivery?

Before delivery, Novohope states that it performs 100% full inspection of products and engages third-party authorities for sampling testing. This quality control process is documented in the company's customer-facing and marketing materials as a standard part of its manufacturing workflow.

In which countries and retail channels have Novohope products been used?

According to a documented case, Novohope products have been used by EM private label production and ODM customized formula development clients from Germany, the UAE, Canada, Australia, France, and the United States. The application involved 200,000 units distributed through chain supermarkets and retail stores, with reported outcomes including boosted category sales and stable repeat orders over a three-year period.